✦ LIBER ✦

Reply: Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia

✍ Scribed by Leon A. Adams; Andrew Mitchell; Gerry MacQuillan; Jonathon Tibballs; Rohan vanden Driesen; Luc Delriviere

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 61 KB
Volume: 14
Category: Article
ISSN: 1527-6465
DOI: 10.1002/lt.21647

No coin nor oath required. For personal study only.

✦ Synopsis

unclear, and further experience in a clinical trial setting is required to clarify this. Lastly, it is exciting to ponder that vascular endothelial growth factor antagonists may have a role in reducing symptoms in the substantial number of HHT patients who are symptomatic but do not require liver transplantation. We agree with Buscarini et al. 1 that only with time will the full clinical role of bevacizumab in symptomatic HHT be made clear.

📜 SIMILAR VOLUMES

Bevacizumab reverses need for liver tran

Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia

✍ Andrew Mitchell; Leon A. Adams; Gerry MacQuillan; Jon Tibballs; Rohan vanden Dri 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease characterized by mucocutaneous and visceral telangiectasia. Hepatic involvement with vascular malformations may lead to portal hypertension, biliary ischemia, and high-output cardiac failure. Liver transplantation is indica

Liver transplantation for cardiac failur

Liver transplantation for cardiac failure in patients with hereditary hemorrhagic telangiectasia

✍ Thierry Thevenot; Claire Vanlemmens; Vincent Di Martino; Marie-Claude Becker; Pi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

Liver involvement in hereditary hemorrhagic telangiectasia may lead to high-output cardiac failure. Few data have been reported on orthotopic liver transplantation (OLT) for these patients. In this paper, we describe two patients treated by OLT as a salvage procedure for cardiac failure, and we revi

ALK-1 mutations in liver transplanted pa

ALK-1 mutations in liver transplanted patients with hereditary hemorrhagic telangiectasia

✍ Loukas Argyriou; Robert Pfitzmann; Lars-Erik Wehner; Stefan Twelkemeyer; Peter N 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Bevacizumab to treat complicated liver v

Bevacizumab to treat complicated liver vascular malformations in hereditary hemorrhagic telangiectasia: A word of caution

✍ Elisabetta Buscarini; Guido Manfredi; Alessandro Zambelli 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB

We read with interest the article by Mitchell et al. 1 dealing with bevacizumab treatment of a patient with hereditary hemorrhagic telangiectasia (HHT), cardiac failure, and portal hypertension due to severe liver vascular malformations (VMs). The treatment reversed the need for liver transplantatio

Reply: The urgent need for evaluating re

Reply: The urgent need for evaluating recurrent primary sclerosing cholangitis in living donor liver transplantation

✍ Edward Biobele Alabraba; Darius Mirza; James Neuberger 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB

We thank Tamura et al. 1 for their thought-provoking letter indicating that there are indeed still a lot of questions to be answered about the recurrence of primary sclerosing cholangitis (PSC). They suggested that a comparison of risk factors and rates of recurrence in living and deceased donor gra